The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation

Diabetes Metab. 2016 Apr;42(2):77-9. doi: 10.1016/j.diabet.2015.11.005. Epub 2015 Dec 10.

Authors

L Monnier¹, D R Owens², G B Bolli³

Affiliations

¹ Institute of Clinical Research, University of Montpellier, 641, avenue Doyen-Giraud, 34093 Montpellier cedex 5, France. Electronic address: louis.monnier@inserm.fr.
² Diabetes Research Group, Swansea University, United Kingdom.
³ Department of Medicine, Perugia University School of Medicine, Perugia, Italy.

PMID: 26688145
DOI: 10.1016/j.diabet.2015.11.005

No abstract available

Keywords: Accumulation risk; New long-acting insulins; Pharmacodynamics.

MeSH terms

Diabetes Mellitus* / drug therapy
Diabetes Mellitus* / physiopathology
Humans
Hypoglycemic Agents* / administration & dosage
Hypoglycemic Agents* / pharmacokinetics
Hypoglycemic Agents* / therapeutic use
Insulin Glargine* / administration & dosage
Insulin Glargine* / pharmacokinetics
Insulin Glargine* / therapeutic use

Substances

Hypoglycemic Agents
Insulin Glargine